Efficacy Capital, Ltd. Sample Contracts

COMMON STOCK PURCHASE AGREEMENT
Common Stock Purchase Agreement • October 7th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances) • Texas

This COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), is made as of September 29, 2008 by and between Repros Therapeutics Inc., a Delaware corporation, with its principal executive offices located at 2408 Timberloch Place, Suite B-7, The Woodlands, Texas 77380 (the “Company”), and Efficacy Capital, LTD (the “Investor”).

AutoNDA by SimpleDocs
STANDSTILL AGREEMENT
Standstill Agreement • March 18th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances) • Delaware

This STANDSTILL AGREEMENT (the “Agreement”), dated as of January 9, 2008, is by and among REPROS THERAPEUTICS INC., a Delaware corporation (the “Issuer”), and EFFICACY CAPITAL, LTD (“Efficacy”).

FIRST AMENDMENT TO STANDSTILL AGREEMENT
Standstill Agreement • October 7th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances) • Delaware

This FIRST AMENDMENT TO STANDSTILL AGREEMENT (the “Amendment”), dated as of July , 2008, is by and between REPROS THERAPEUTICS INC., a Delaware corporation (the “Issuer”), and EFFICACY CAPITAL, LTD (“Efficacy”).

JOINT FILING AGREEMENT
Joint Filing Agreement • March 18th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances)

In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Repros Therapeutics, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of March 12, 2008.

JOINT FILING AGREEMENT
Joint Filing Agreement • March 12th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances)

In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13G (including amendments thereto) with regard to the common stock of Repros Therapeutics, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of December 31, 2006.

Initial Director’s Grant)
Non-Employee Director's Stock Option Agreement • October 7th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances) • Delaware

AGREEMENT made as of the 26th day of September 2008, between REPROS THERAPEUTICS INC., a Delaware corporation (the “Company”), and Mark Lappe (“Director”).

SECOND AMENDMENT TO STANDSTILL AGREEMENT
Standstill Agreement • October 7th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances) • Delaware

This SECOND AMENDMENT TO STANDSTILL AGREEMENT (the “Amendment”), dated as of October 2, 2008, is by and between REPROS THERAPEUTICS INC., a Delaware corporation (the “Issuer”), and EFFICACY CAPITAL, LTD (“Efficacy”).

JOINT FILING AGREEMENT
Joint Filing Agreement • October 31st, 2007 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances)

In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13G (including amendments thereto) with regard to the common stock of Repros Therapeutics, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of December 31, 2006.

AGREEMENT REGARDING JOINT FILING
Joint Filing Agreement • October 10th, 2006 • Efficacy Capital, Ltd. • Pharmaceutical preparations

The undersigned, Efficacy Capital Ltd., Efficacy Biotech Fund, L.P., Efficacy Biotech Fund Ltd., Efficacy Biotech Master Fund Ltd., Jon Faiz Kayyem and Mark Lappe, hereby agree and acknowledge that the information required by the Schedule 13D to which this Agreement is attached as an exhibit, is filed on behalf of each of them. The undersigned further agree that any amendments or supplements thereto shall also be filed on behalf of each of them.

AGREEMENT REGARDING JOINT FILING
Joint Filing Agreement • November 20th, 2006 • Efficacy Capital, Ltd. • Pharmaceutical preparations

The undersigned, Efficacy Capital Ltd., Efficacy Biotech Fund, L.P., Efficacy Biotech Fund Ltd., Efficacy Biotech Master Fund Ltd., Jon Faiz Kayyem and Mark Lappe, hereby agree and acknowledge that the information required by the Schedule 13D to which this Agreement is attached as an exhibit, is filed on behalf of each of them. The undersigned further agree that any amendments or supplements thereto shall also be filed on behalf of each of them.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!